SYS-CON MEDIA Authors: Kevin Benedict, Gilad Parann-Nissany, Unitiv Blog, RealWire News Distribution, Jason Bloomberg

News Feed Item

Precision Therapeutics Supports the Annual National Ovarian Cancer Coalition (NOCC) Run/Walk to Break the Silence

Precision Therapeutics is proud to be a national sponsor of the NOCC 2014 Run/Walk to Break the Silence on Ovarian Cancer. In addition to sponsoring their local Pittsburgh Chapter event, Precision will be present at NOCC run/walks taking place in Austin on August 10th, Boston on September 7th, Dallas on September 21st, and Providence on September 28th.

The goal of these events is to celebrate survivors, remember those lost to ovarian cancer and raise awareness about the disease. As leaders in personalizing treatment for ovarian cancer patients, Precision understands the importance of these events and continues to encourage employees to contribute by walking alongside ovarian cancer patients, survivors and loved ones to help strengthen the bond that has been created in the fight of this deadly disease.

As part of its national sponsorship, Precision will have an exhibit space in each city and will provide every employee participating with a pre-paid registration.

“We are so honored to be working with the NOCC on a larger scale this year. They continue to be a frontrunner in ovarian cancer education and awareness, and we are delighted to be affiliated with such an amazing group,” said Sean McDonald, President and CEO of Precision Therapeutics. “As a company we have always been dedicated to improving the outcomes of cancer patients, and with this partnership we are one step closer to achieving that goal.” Precision specializes in developing products to help guide physicians and patients with difficult clinical decisions throughout the spectrum of cancer care.

The Pittsburgh NOCC Walk to Break the Silence will take place on Sunday, September 14, 2014 at the North Park Boathouse. For more information on the NOCC run/walks across the country, please visit www.ovarian.org.

About Ovarian Cancer:
More than 22,000 women in the United States are newly-diagnosed with ovarian cancer each year. Approximately 80% of all women with ovarian cancer have their disease recur, and 20-30% of recurrences occur within 6 months of the end of first-line therapy. The majority of patients with ovarian cancer (more than 70%), present with advanced disease at initial diagnosis, and women with advanced ovarian cancer tend to have multiple relapses and undergo several rounds of chemotherapy. There have been modest gains in ovarian cancer statistics in the last two decades, with only a small percentage of improvement in overall survival rates for recurrent ovarian cancer.

About Precision Therapeutics:
Precision Therapeutics, Inc., a life-science company located in Pittsburgh, PA, is dedicated to personalizing cancer care and improving patient outcomes. As leaders in the science of individualizing cancer therapy, Precision develops novel markers to help guide treatment decisions based on the biological processes of each individual’s cancer.

Precision’s ChemoFx test is a proprietary drug response marker which quantifies an individual gynecologic cancer patient’s probable tumor response to a range of standard chemotherapeutic options. ChemoFx has been validated in previously conducted clinical studies, with data demonstrating a 14-month improvement in overall survival and 50% increase in progression-free survival when recurrent ovarian cancer patients are treated with ‘responsive’ therapies as indicated by ChemoFx.

In addition to ChemoFx, Precision also offers BioSpeciFx®, a portfolio of clinically relevant molecular tests that provide information about drug response and patient prognosis. For more information, visit: www.precisiontherapeutics.com or www.chemofx.com.

More Stories By Business Wire

Copyright © 2009 Business Wire. All rights reserved. Republication or redistribution of Business Wire content is expressly prohibited without the prior written consent of Business Wire. Business Wire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.